Histologic and inflammatory lamellar changes in horses with oligofructose-induced laminitis treated with a CXCR1/2 antagonist

Leonardo R. de Lima, Heloisa M.F. Mendes, Frederico M. Soriani, Danielle G. de Souza, Geraldo Eleno S. Alves, Mauro M. Teixeira and Rafael R. Faleiros


With the hypothesis that blocking chemokine signaling can ameliorate acute laminitis, the aim was to evaluate the therapeutic effect of intravenous DF1681B, a selective antagonist for CXCR1 and CXCR2 (chemokine receptors), in an oligofructose equine laminitis model. To twelve mixed breed clinically healthy horses with no previous history of hoof-related lameness was administered oligofructose (10g/kg given by nasogastric tube) and divided into two groups: treated (intravenous DF1681B at 30mg/kg 6, 12, 18, and 24h after oligofructose) and non-treated groups. Laminar biopsies were performed before and 12, 36, and 72h after administering oligofructose. Samples were stained with periodic acid-Schiff (PAS) and scored from 0 to 6 according to epidermal cell and basal membrane changes. The IL-1β, IL-6, and CXCL1 RNA expressions were determined by RT-PCR. Parametric and non-parametric tests were used to compare times within each group (P<0.05). The PAS grades and IL-1β and IL-6 RNA expression increased in the non-treated group, but remained constant in the treated horses. In conclusion, DF1681B therapy reduced laminar inflammation and epidermal deterioration in treated horses. CXCR1/2 blockage should be considered therapeutically for equine acute laminitis.

INDEX TERMS: Neutrophil, chemokine, CXC receptors, horse, laminitis.
tantes nos cavalos tratados. Em conclusão, a terapia por DF1681B reduziu a inflamação laminar e a deterioração epidêrmica em equinos submetidos ao modelo de intoxicação por oligofructose. O bloqueio de receptores CXCR1/2 deve ser considerado como uma opção terapêutica para prevenção da laminitis aguda de equinos.

TERMOS DE INDEXAÇÃO: Neutrófilos, quimiocinas, receptores CXC, cavalo, laminitis.

INTRODUCTION

The equine hoof is extremely resistant to the demanding external environment; however, the destruction of its microstructure by laminitis has catastrophic consequences for the welfare and even survival of the affected horse. The damaged dermal-epidermal junction destroys adherence between the hoof and distal phalanx, preventing weight bearing and locomotion. A strong correlation between microstructural damage and the severity of clinical signs was established (Pollitt 1996).

Dermal-epidermal junction collapse is common in laminitis of numerous etiologies, but the initial event triggering the structural failure remains poorly understood (Katz & Bailey 2012). Multiple studies propose resident leukocyte activation in the lamella and leukocytic infiltration from the bloodstream, associated with systemic inflammatory response syndrome (SIRS), as probable mechanisms that initiate structural failure (Black et al. 2006, Hurley et al. 2006, Belknap et al. 2007, Loftus et al. 2007, Stewart et al. 2009, Faleiros et al. 2009b, Faleiros et al. 2011a). Increased pro-inflammatory cytokine expression (mainly IL-1β and IL-6), as well as CXC and CCR chemokines, during the developmental stage, indicates that these molecules may play an important role in leukocyte migration in the early events of laminitis (Belknap et al. 2007, Faleiros et al. 2009a, Leise et al. 2011, Faleiros et al. 2011b, Visser et al. 2011).

CXCR1 and CXCR2 are G protein receptors and have a high affinity for chemokines that are glutamine-leucine-arginine positive (Mukaida 2003, Kim et al. 2011). These chemokines have been detected in several human and equine tissues affected by inflammatory conditions associated with severe neutrophil infiltration (Franchini et al. 2000, Giustizieri et al. 2001, Ainsworth et al. 2006, Woodman et al. 2006). Selective pharmacologic blockade of CXCR1/2 is a promising strategy for controlling inflammation and could potentially treat and prevent equine laminitis (Bizzarri et al. 2006, Coelho et al. 2008).

DF1681B is a CXCR1/2 noncompetitive, allosteric antagonist and potentially inhibits a variety of chemokine-induced biological activities (Souza et al. 2004, Bizzarri et al. 2006, Gorio et al. 2007, Zarbock et al. 2008, Marsh et al. 2011). DF1681B reduced secondary spinal cord degeneration in a rat model of trauma, as well as reduced oligodendrocyte apoptosis and neutrophil infiltration of ED-2 positive cells. In addition, the recovery rate for hind limb movement was higher in treated animals (Gorio et al. 2007). In another study, DF1681B inhibited neutrophil adhesion to synovial endothelium, reducing neutrophilic recruitment into the synovial membrane, and alleviating tissue damage in a rat model of arthritis (Coelho et al. 2008). DF1681B was also shown to reduce ischemic and intestinal reperfusion injury in mice by decreasing vascular permeability and neutrophil influx (Souza et al. 2004).

Despite recent evidence indicating leukocyte involvement in laminitis development (Black et al. 2006, Hurley et al. 2006, Belknap et al. 2007, Loftus et al. 2007, Stewart et al. 2009, Faleiros et al. 2009b, Faleiros et al. 2011a), and the therapeutic potential of DF1681B for neutrophil migration in rodents, this drug has not yet been studied in horses.

The present study evaluated the effect of DF1681B, a CXCR1/2 antagonist, on histological lesions, and the IL-1β, IL-6, and CXCL1 expressions in equine lamellar tissue following oligofructose-induced laminitis.

MATERIALS AND METHODS

Twelve mixed breed horses, comprising four castrated males and eight non-pregnant females, aged (mean±SD) 7±3.5 years, weighing 305±35 kg, and with a mean body condition score of 5±1/9 were evaluated. Horses were considered clinically normal based on physical and hematological exams and had no previous history of hoof-related lameness. After a 2-week adaptation period of consuming only grass hay (Cynodon sp.), the horses were randomly divided into two groups: treated (n=6) and non-treated (n=6). This protocol was approved by the Ethics Committee on Animal Use and Experimentation of UFMG (CEUA / UFMG 225/2009).

To induce laminitis, all horses were administered 10g/kg of oligofructose (Rafitlose P95, EmbrafarmaceuticalaExpertise, São Paulo/SP, Brazil) diluted in 3L of water through a nasogastric tube. At 6, 12, 18, and 24h after oligofructose administration, horses in the treated group received DF1681B (Dompé Pharma SpA Research Center, L’Aquila, Italy), intravenously, at 30mg/kg diluted in 500mL of sterile 0.9% saline. The solution was filtered through a 0.22 μm bacteriological filter (Biofil syringe filter, Jet Bio-Filtration Products Co., Guangzhou, China) before administration.

Before (T0) and 12, 36, and 72h after oligofructose administration, biopsies were taken sequentially from the left pelvic (T0), right pelvic (T12), right thoracic (T36), and left thoracic (T72) hooves of each horse. The horses were sedated with 10% xylazine (1mg/kg intravenously), and perineural anesthesia (5mL of zaine (1mg/kg intravenously), and perineural anesthesia (5mL of
Histologic and inflammatory lamellar changes in horses with oligofructose-induced laminitis treated with a CXCR1/2 antagonist

Frozen samples were thawed in Petri dishes. The deep dermis was already lost during biopsy; the excess stratum corneum was removed with a scalpel. RNA was extracted, beginning by adding trizol (Invitrogen, Carlsbad, CA, USA) at 1mL/100 mg of tissue, followed by adding chloroform; the samples were then homogenized and vortexed. The samples were centrifuged at 12,000 rpm, for 10 min at 4°C. Between samples, the homogenizer was rinsed using 50 mL Falcon tubes containing distilled water, followed by 70% isopropanol, then distilled water again.

After centrifugation, the aqueous phase containing RNA was transferred into new microfuge tubes containing 500μL of isopropanol. The sample was centrifuged again at 12,000 rpm, for 10 min, at 4°C, generating an RNA pellet. The supernatant was discarded, and 150μL of 70% ethanol in DEPC (diethyl pyrocarbonate) was slowly added to the RNA pellet. The sample was once more centrifuged at 12,000 rpm and 4°C for 10 min. The 70% ethanol was carefully discarded to avoid disturbing the RNA pellet. The microtubes were stored open on a sheet of paper to dry the pellet.

After resuspension and spectrophotometric quantification, the RNA was converted into cDNA by adding oligo dT (50mmol/L) to the RNA sample, which was then heated to 70°C for 5 min and abruptly cooled on ice. The cDNA was generated using 1μL of dNTP (10mmol/L), 1μL of DTT (1 M), 4μL of SuperScript Buffer (5×), and 1μL of RNase (SuperScript III Reverse Transcriptase, Invitrogen, Carlsbad, CA, USA); the mixture was subjected to a thermal cycler for 90 min followed by 15 min at 75°C.

The primer sequences are described in Table 1. The scale synthesis was 25nmol, desalted, and the prepared primers were diluted to 5μmol/L. The real-time PCR was performed using 5μL of SYBR Green PCR Master Mix (SYBR Green PCR Master Mix, Applied Biosystems, Grand Island, NY, USA), 1μL of forward primer, 1μL of reverse primer, and 1μL of ultrapure water with a real-time PCR device (7500 Fast Real Time PCR, Applied Biosystems, Grand Island, NY, USA). The results were analyzed using the 2 ΔΔCt method. This processing involves identifying and removing outlying individuals whose assay results exhibit marked, and likely artifactual, deviation from the other assay results (Chow et al. 2012).

Data were analyzed with statistical software (Prism 5, GraphPad Software, Inc., La Jolla, CA, USA). The histologic data were compared within each group over time using the Mann–Whitney test. PCR data were compared within each group over time using the one-way ANOVA followed by the Newman-Keuls test. Significance was designated at P<0.05 for all tests.

**RESULTS**

The biopsy procedure was well tolerated by the subjects with no major complications observed. There was intense hemorrhage at the biopsy site immediately upon removing the sample, but this ceased with manual compression. The skin punch biopsy coupled to the drill produced appropriate samples to study the lamellar epidermis and dermal-epidermal junction. However, most of the sublamellar dermis (deep dermis) was lost during biopsy.

| Table 1. cDNA primer sequences used for real-time PCR |
|-------------------|-------------|-----------|
| Gene    | Direction | Sequence       |
| β-actin  | Forward    | 5'-TTCCCTGGAGAAGAGCTACGA-3' |
| β-actin  | Reverse    | 5'-TTTCGTTAGTGCAAGGAT-3' |
| IL-1β    | Forward    | 5'-GCTGCTTTCCCTATATTAGTG-3' |
| IL-1β    | Reverse    | 5'-AGTGAAGCAGAGGTTGAG-3' |
| IL-6     | Forward    | 5'-CTCTGCAAGAGGCTCAGC-3' |
| IL-6     | Reverse    | 5'-GTGAAAGACAGTGAGGAT-3' |
| CXCL1    | Forward    | 5'-GCCAACGGCAGCACACGTA-3' |
| CXCL1    | Reverse    | 5'-GCCAACGGCAGCACACGTA-3' |

**Fig.1.** Hoof lamellar samples taken from biopsy procedure technique using a Keyes dermal punch.

**Fig.2.** Mean (± SE) lamellar tissue PAS grades before (0) and after (12, 36, and 72h) laminitis induction (oligofructose model) in horses treated or not with DF1681B.

**Fig.3.** Mean (± SE) fold increase change in IL-1β, IL-6, and CXCL1 RNA expression in lamellar tissue before (0) and after (12, 36, and 72h) laminitis induction (oligofructose model) in horses treated or not with DF1681B.
On histologic analysis, most samples in the untreated group were graded between 2 and 3 after oligofructose administration, and the increase from basal values was statistically significant at 24 and 36h. By contrast, lamellar sections in the treated group were graded between 1 and 2, which was not a significant change (Fig.2).

The pro-inflammatory chemokine mRNA expression was significantly increased in the untreated group alone (Fig.3). Twelve hours after oligofructose administration, IL-1β expression increased 20-fold (P=0.0016) and the IL-6 expression increased 8-fold (P=0.003) in the untreated group. The CXCL1 expression peaked at 36h in the untreated group, however, this change was not statistically significant (P=0.16) compared to baseline.

**DISCUSSION**

This is the first known study evaluating a CXCR1/2 receptor antagonist in horses. Based on reported DF1681B benefits in decreasing neutrophilic tissue damage in rodent models of spinal trauma (Gorio et al. 2007), intestinal ischemia and reperfusion (Souza et al. 2004), acute lung injury (Zarbock et al. 2008), and antigen-induced arthritis (Rabbit et al. 2008), we examined its possible therapeutic effects on equine laminitis. The lack of both a PAS grade increase and an IL-1β and IL-6 increase at 12h in the treated group suggests that DF1681B mitigates the inflammatory damage in the lamellar tissue in oligofructose-induced equine laminitis. Though promising, these findings are preliminary, and our model has several notable limitations.

Most studies using an equine laminitis model performed euthanasia to obtain the lamellar samples (French et al. 2004, Hurley et al. 2006, Van Eps et al. 2006, Belknap et al. 2007). This methodology is advantageous because numerous hoof lamellae, other tissues, and organ samples are available for each horse. However, a large number of horses are necessary to evaluate the evolution of lesions over time because each time point demands its own experimental group. This method increases the cost and hampers new drug development. To minimize animal usage and evaluate DF1681B, a new anti-inflammatory drug already assessed in human clinical trials, biopsy was used to harvest lamellar tissues.

Biopsies were taken from all feet of each horse based on a recent study demonstrating that histologic lesions develop evenly across all four hooves in experimentally induced laminitis (Leise et al. 2012). Feet were biopsied sequentially, and the forefeet were biopsied at the later time points (36 and 72h) because they are more prone to developing laminitis lesions. A prior study revealed significant variability in the carbohydrate overload-induced laminitis lesions between samples obtained from a single hoof (Faleiros et al. 2011a); therefore, three samples were taken from each hoof.

Biopsy has been used to histologically evaluate equine lamella by other authors (Hanly et al. 2009, Paes Leme et al. 2010, Visser & Pollitt 2011, Gravena et al. 2012), including serial collection (Hanly et al. 2009, Visser & Pollitt 2011). In the present study, a new hoof biopsy technique was used. Attaching a skin biopsy punch device to a drill provided a quick and easy way to obtain lamellar tissue samples. However, the sublamellar (deep) dermis was lost in most samples during collection, which limits the histologic investigation to the lamellar stratum.

Histologic signs of laminitis were found in all horses in the untreated group after oligofructose administration. However, the epidermis and basement membrane PAS grades were consistently low (2 to 3) compared to other studies of carbohydrate overload models (Faleiros et al. 2011a, Visser & Pollitt 2011). van Eps & Pollitt (2006) reported extensive epidermal cell detachment from the basement membrane (corresponding to score 5) 48 h after administering the same oligofructose dose. Similarly, in a cornstarch model using the same PAS grade system, PAS scores between 3 and 4 occurred in 50% of subjects between 20 and 48h (Faleiros et al. 2011a).

However, the histologically mild laminitis is consistent with another study reporting mild clinical signs of laminitis in these same horses (Lima et al. 2013). Several factors may underlie the lower severity of inflammation found in this study compared to others (van Eps & Pollitt 2006, Faleiros et al. 2011a). However, the low body weight of these horses appears to be the primary cause. A limited amount of DF1681B was available for this study, therefore we elected to use relatively small horses. There are reports of absent to mild clinical signs in light weight horses with oligofructose-induced laminitis (van Eps, personal communication 2012).

Another factor potentially causing the mild clinical and lamellar inflammation in the present model is the intense hemorrhage following biopsy. Oligofructose is believed to disturb the equine large intestinal microenvironment, causing systemic absorption of pathogen-associated molecular patterns (PAMPs) produced by atypical lactic fermentation and damage-associated molecular patterns (DAMPs) originating from the damaged intestine; both can trigger lamellar inflammation (Milinovich et al. 2006, 2010, Belknap et al. 2010). Hemorrhage at the biopsied sites beginning 6 h after oligofructose administration may deplete the PAMPs and DAMPs mitigating the initial lamellar inflammation. Notably, hemorrhage has been used empirically to treat laminitis for the last 2000 years and continues to be used even today (Heymering 2010). Nevertheless, this hypothesis should be confirmed by additional studies.

DF1681B has a variable elimination half-life ranging from 0.5h in rats to 10h in dogs (Gorio et al. 2007); there is no information for horses presently. Thus, our protocol comprised four doses (30mg/kg) administered at 6-hour intervals. This protocol was designed to counter the developmental phase (6-30h after carbohydrate administration) when the major pro-inflammatory cytokine expression (Leise et al. 2011, Visser & Pollitt 2011), chemokines (Faleiros et al. 2011b), and leukocyte immigration (Faleiros et al. 2011a, Visser & Pollitt 2011) begin in the lamellae.

Because there are no DF1681B pharmacokinetic studies in horses, it is unknown whether a different protocol would improve the therapeutic efficacy in this laminitis model. It is also unclear whether treating the horse before the oligofructose challenge would produce a different res-
ponse. However, in rats, administered DF1681B 40 min before inducing arthritis, joint lesions were minimized 3 and 6 h after (Coelho et al. 2008). Intestinal lesions were ameliorated when DF1681B was administered before intestinal reperfusion in rats (Souza et al. 2004), but the best therapeutic effect following spinal cord trauma in rats required 7 days of treatment (Gorio et al. 2007). Similarly, in a murine spinal injury model, the best therapeutic results were obtained when plasma levels were maintained at 8 µg/mL (Gorio et al. 2007). This opens a wide avenue for further studies of varying dosing regimens in horses.

CONCLUSION

Despite the limitations of the employed model, these preliminary findings showed that DF1681B therapy prevented lamellar inflammation and dermal-epidermal junction damage in horses subjected to oligofructose-induced laminitis. Future studies will clarify the therapeutic benefits of CXCR1/2 antagonists in equine laminitis.

Acknowledgements.- The authors thank Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG) for their financial support. The Duke University School of Medicine, North Carolina, for use of their facilities and equipment. A guide for the care and use of laboratory animals (8th ed.) was followed. This study was performed according to the ethical standards of the 1985 Declaration of Helsinki and the Brazilian Animal Protection Law (PL 10,889/04).

REFERENCES


Bizzarri C., Becari A.R., Bertini M.R., Giorgini S. & Allegretti M. 2006. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharm. Ther. 112:139-149.


